Emerging Issues in Dietary Supplement Regulatory Oversight

/in /by

Emerging Issues in Dietary Supplement Regulatory Oversight

The dietary supplement regulatory oversight needs immediate attention for authenticity verification and quality management of products along with personal nutrition’s rising influence during the next five years. Professional oversight must address food labelling precision needs and adulteration prevention because diverse regulatory environments coincide with advanced food components (“The Food Forum 30th Anniversary,” 2024). Rapid market expansion of supplements and changing consumer needs for natural functional ingredients make it necessary to strengthen regulatory oversight. Modern regulatory authorities must define regulations that ensure safe nutrition products for consumers while encouraging innovation development (“The Food Forum 30th Anniversary,” 2024).

Due to emerging health concerns, the United States needs to take decisive steps to improve dietary supplement regulation. Enforcing strong ingredient verification methods through mandatory supplier documents helps manufacturers avoid product contamination and incorrect labeling practices. The 30th-anniversary event of “The Food Forum” in 2024 highlights how collaborations between regulators worldwide and data-based technology will strengthen oversight procedures and increase transparency. Discussed methods should establish required third-party testing, which verifies dietary supplement purity and compositions according to Good Manufacturing Practice requirements. Real-time non-compliant product detection can be possible by integrating artificial intelligence and machine learning technologies, which help protect public health, according to Gillings et al. (2021).

The findings of Cadwallader (2022) in “Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention?” further support my opinions above. The FDA currently makes dietary supplements a positive safety assumption before requiring manufacturers to prove their products’ worth, according to Cadwallader (2022). The author stresses that existing regulations require more supervision because the market experiences a growing number of adulterated and mislabeled products. The FDA reports described by Cadwallader (2022) show that inspection results revealed violations in more than half of checked supplement manufacturing facilities. The author suggests that improved doctor and consumer education would help reduce the dangers of supplement utilization.

Through these strategies, the U.S. can strengthen safer dietary supplement oversight and support responsible industry expansion. When these priorities receive attention, a regulatory environment that promotes transparency and accountability emerges.

References

Cadwallader, A. B. (2022). Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention?. AMA Journal of Ethics, 24(5), 410-418. https://doi.org/10.1186/s41181-021-00123-2

Gillings, N., Hjelstuen, O., Ballinger, J., Behe, M., Decristoforo, C., Elsinga, P., … & Todde, S. (2021). Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI radiopharmacy and chemistry, 6, 1-22.

The Food Forum 30th Anniversary. (2024). In National Academies Press eBooks. https://doi.org/10.17226/27771

Emerging Issues in Dietary Supplement Regulatory Oversight

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

NU 665 WEEK 13: Crisis Management Case Study

/in /by

NU 665 WEEK 13: Crisis Management Case Study

  1. What important information is missing from the case study?

The case study lacks several critical pieces of information necessary for a comprehensive evaluation. The case fails to provide necessary psychiatric details, which include both past medical diagnoses and evaluations of drug treatment and medication adherence. The healthcare document does not include vital information on Marly’s childbirth delivery records or her potential postpartum medical issues, which could involve preeclampsia as well as infections. The clinical staff should get an extensive picture of Marly’s drug history, particularly concerning her cocaine, methamphetamine, alcohol, and marijuana use, which influences her current state. A physician must evaluate brain functions to detect delirium and other medical conditions responsible for Marly’s erratic behavior and confusion. The case study also lacks essential details regarding how the patient interacts with protective services agencies and information about the interventions put in place to address potential abuse from her boyfriend.

  1. Discuss normal developmental achievements and potential vulnerabilities.

Typical developmental objectives for people of 30 years old include maintaining consistent employment status, establishing independent living arrangements, forming important relationships, and emotional stability regulation. The vulnerabilities Marly demonstrates appear to limit her ability to achieve these developmental benchmarks. The combination of psychiatric hospital admissions, substance use, and suspected domestic violence reveals unstable emotional and social development for Marly. Studies indicate that women with psychiatric backgrounds face heightened vulnerability to severe mood disorders, leading to postpartum depression and postpartum psychosis during the postnatal period (Garapati et al., 2023). Motherhood after giving birth places women at higher risk of developing mood disorders, primarily targeting those who have pre-existing mental illnesses. Research has verified that hormonal fluctuations, inadequate psychosocial assistance, and financial challenges amplify the postpartum mood symptoms (Garapati et al., 2023).

The combination of depression and suicidal tendencies across generations places Marly at higher risk for psychiatric difficulties because genetics appears to influence mental conditions. Postpartum mental health difficulties affect people with mood disorder family backgrounds significantly because genetic elements combine with environmental triggers to affect their psychological state in the critical postpartum period (Garapati et al., 2023). Marly faces multiple risk factors for mental health decline because she lives in public housing and faces financial hardships while caring for her three young children. Postpartum depression increases in frequency among mothers who face financial hardship, insufficient mental health care, and lack social support networks, as per Garapati et al. (2023). The combination of living in public housing with stress from raising three young kids makes her susceptible to greater mental health decline.

  1. What precipitating factors could be contributing to the current symptoms?

Various reasons led to Marly’s present psychological state. The birth of her newborn exposes her to a great risk of developing severe postpartum mood disturbances, including postpartum psychosis. Uccella et al. (2023) highlight that proper postpartum mood disorder diagnoses and differentiation help healthcare providers provide early interventions, which yield enhanced treatment results. Healthcare professionals need to identify symptoms of mood variations as hormone changes become drastic during this period.

The history of cocaine, methamphetamine, and alcohol use has made her susceptible to future substance relapse because these substances often lead to agitation, psychosis, and paranoia. A complete postpartum mental health evaluation examines biological, psychological, and socioeconomic risks to ensure accurate diagnosis, support, and treatment based on research by Uccella et al. (2023). Marly faces increased risk for postpartum mood disorders because her existing insomnia syndrome and persistent sleep loss create high vulnerability to psychiatric disorders, which commonly stem from sleep disturbances.

Medical specialists identify postpartum mental health as a condition resulting from both psychological pressures and biological elements. Uccella et al. show how mothers such as Marly experience psychological distress because of money problems, child-related responsibilities, and domestic violence situations. The substance use and aggressive behavior of her boyfriend trigger both paranoia and intense anxiety in Marly. Assessing risks after childbirth demands that mental health professionals create both evaluation tools and supportive systems. Further studies also demonstrate that healthcare barriers and stigma hinder long-term outcomes, but effective, accessible care with comprehensive intervention strategies specifically for mothers remains essential.

  1. What is the differential diagnosis?

A set of psychiatric disorders requires analysis based on the observed symptoms exhibited by Marly. The postpartum psychosis (PPP) arises as a possible and severe condition that generates hallucinations and leads to delusions, mood disturbances, and behavioral changes. The unique nature of PPP distinguishes it from other psychotic disorders because it directly affects mother-infant relationships and necessitates specialized assessment techniques according to Friedman et al. (2023). Knowledge about PPP’s biological foundation would enable early recognition and treatment; therefore, physicians should evaluate Marly for psychiatric and medical aspects.

Monitoring substance-induced psychotic disorder remains essential because the patient’s history of stimulant abuse triggers symptoms of paranoia, aggression, and unpredictable behavior. Medical professionals should consider bipolar disorder when patients experience psychotic symptoms, documented episodes of bipolar mood swings, and psychiatric hospitalizations. Evaluation of schizoaffective disorder symptoms is needed because of the patient’s agitated and disordered thought patterns.

Medical examinations must confirm if the patient’s elevated blood pressure measurement of 160/90 will cause hypertensive encephalopathy, and laboratory testing must eliminate delirium stemming from potential metabolic or infectious conditions. Several healthcare professionals must evaluate Marly because she needs diagnostic approaches that align with research evidence and recognition of her maternal responsibilities.

  1. Describe the etiology of the primary diagnosis.

The main diagnosis is postpartum psychosis, which emerges from hormonal changes together with stress exposure and existing susceptibility to mood disorders. The sudden estrogen-progesterone hormonal shifts following childbirth create psychiatric symptoms that are worsened when new mothers lack sufficient sleep (Sharma et al., 2022). The vulnerability described in Marly’s psychiatric background became worse because of hormonal changes that followed childbirth. People who use cocaine and methamphetamine experience psychotic symptoms since these substances increase arousal levels and create paranoia, which leads to aggressive behavior (Sharma et al., 2022). Continued drug use distorts brain functions, which leads to higher psychiatric risk levels when people stop taking drugs. It is worth mentioning that multiple biological factors, including heredity combined with chemical and psychological stressors, seem to drive both the formation and recurrence of bipolar disorder.

  1. How would you manage this crisis situation?

The top priority for Marly’s crisis management requires protecting her safety alongside safeguarding the people near her. The combination of her agitation, along with paranoia and aggression, requires intensive attention through admission to a psychiatric unit, which will safeguard both herself and others. An involuntary hospital admission may become necessary if the patient presents a threat to herself or anyone else. Medication therapy with antipsychotics supports the stabilization of Marly’s psychotic symptoms, which are at present acute. Supportive care and detoxification procedures should be implemented immediately when substance intoxication is recognized (Weber et al., 2021). The patient needs complete medical evaluations and psychiatric assessments, including diagnostic tests and medical imaging, to exclude potential conditions. Social services need to evaluate her children’s welfare and should offer assistance in cases involving domestic violence issues. Stabilization of her condition and long-term care planning must integrate medical services from psychiatry, along with social work and addiction treatment expertise.

  1. What are the nonpharmacologic interventions that would help?

Psychosocial Support: Supporting Marly requires comprehensive psychosocial measures that include crisis counseling to manage any current distress. The adoption of trauma-informed methodologies proves essential in this context because domestic violence might exist within her situation. Postpartum mother support groups, recovery groups for mental health and substance abuse issues, offer extended emotional and social backing to affected individuals like Marly (Weber et al., 2021).

Crisis Intervention and Safety Planning: A crisis intervention plan and safety plan should be implemented due to Marly’s unpredictable behaviors, combined with her destructive mood swings. Prior interventions must include removing current stressors alongside a safety assessment that might require social service intervention. Detected domestic violence will trigger access to designated shelters and legal support services for the individual.

Cognitive-Behavioral Therapy (CBT) and Psychotherapy: After stabilization, Marly needs therapy for treating mood swings, substance abuse problems, and dealing with emotional instability. Marly will benefit from CBT therapy to learn different techniques that both calm stress and decrease the chances of returning to past harmful behaviors. If past abuse serves as a cause for current problems, then trauma-focused therapy should become part of the treatment strategy (Weber et al., 2021).

Substance Use Treatment: An experienced expert needs to provide Marly with professional addiction treatment through organized substance abuse treatment planning since she has experienced cocaine, methamphetamine, and alcohol use. The substance treatment plan for such patients includes inpatient treatments, outpatient therapy, and participation in recovery groups like Narcotics Anonymous (NA) or Alcoholics Anonymous (AA) (Weber et al., 2021).

Community and Social Resources: By connecting Marly to housing support programs, financial assistance, and neighborhood-based mental health programs, her stability will improve. The social service system needs to provide Marly with safe housing opportunities in a secure neighborhood.

  1. What are the psychopharmacological interventions that would help?

Antipsychotics for Psychosis and Agitation: Antipsychotic medications such as olanzapine, risperidone, or haloperidol should be prescribed for Marly because her symptoms include paranoia, confusion, and aggressive behavior. The prescribed medications in this category reduce psychotic symptoms as well as agitation. Among second-generation antipsychotic drugs, the preferred choice for administration rests with olanzapine because it poses minimal risks for generating extrapyramidal side effects (Johansen et al., 2020).

Mood Stabilizers for Underlying Bipolar Disorder: Prescription of lithium or valproate by a psychiatrist is necessary to treat Marly since she shows signs of bipolar disorder with psychotic features. Medical staff must monitor both kidney function and thyroid status before administering lithium and should use caution while prescribing valproate because it poses teratogenic risks to patients.

Benzodiazepines for Acute Agitation: The treatment of acute agitation with short-term benzodiazepines like lorazepam should be considered only when Marly poses a danger to herself or others. Care should be taken when prescribing benzodiazepines due to her substance usage background because these drugs have known dependence risks (Johansen et al., 2020).

Antidepressants if Postpartum Depression is Present: A healthcare provider will prescribe an antidepressant from the selective serotonin reuptake inhibitor class (SSRI), such as sertraline, if Marly continues to show depressive symptoms after stabilization. Sertraline functions as a preferred treatment option for postpartum patients because of its minimal risks to breastfeeding mothers (Johansen et al., 2020).

Breastfeeding Considerations: New mothers like Marly who breastfeed require medicine choices that will not affect their nursing ability. Nurses must monitor infants when specific antipsychotic medications and mood stabilizers are used (Weber et al., 2021). Professional collaboration between the nurse, an obstetrician, and a lactation consultant is strongly recommended.

  1. Identify safety risks and how they should be dealt with in the treatment plan.

Risk of Harm to Self or Others: The aggressive conduct, paranoid behavior, and psychiatric admission records suggest Marly poses a severe danger to herself and others. Therefore, continuous staff supervision must be provided to her until her condition improves. Psychiatric hold laws enabling involuntary hospitalization through 72-hour holds should be implemented when she refuses treatment and demonstrates a high risk of harm.

Domestic Violence and Housing Instability: A domestic violence situation might exist as her mother believes her boyfriend abuses her, which creates concerns about intimate partner violence (IPV). Social services need to collaborate with the client to build a safety plan that contains both shelter services for domestic abuse survivors and legal advice. Safe and permanently stable housing needs to be included within her comprehensive long-term care strategy.

Substance Use Relapse: The fact that Marly formerly used cocaine, methamphetamine, alcohol, and marijuana creates a high risk for her to return to substance abuse. The treatment program should incorporate substance abuse therapy and possible hospital-based detoxification in addition to relapse prevention measures. Medications like naltrexone or acamprosate may help with cravings (Adams et al., 2021).

Noncompliance with Treatment: The existing psychiatric hospitalizations and unpredictable actions of Marly increase her likelihood of nonadhering to medication prescriptions and post-hospital care appointments. The structured discharge plan should contain necessary outpatient psychiatric follow-up appointments, case management support, and additional home visits if required (Adams et al., 2021).

References

Adams, Z. M., Ginapp, C. M., Price, C. R., Qin, Y., Madden, L. M., Yonkers, K., & Meyer, J. P. (2021). “A good mother”: Impact of motherhood identity on women’s substance use and engagement in treatment across the lifespan. Journal of Substance Abuse Treatment, 130, 108474. https://doi.org/10.1016/j.jsat.2021.108474

Friedman, S. H., Reed, E., & Ross, N. E. (2023). Postpartum psychosis. Current psychiatry reports, 25(2), 65-72.

Garapati, J., Jajoo, S., Aradhya, D., Reddy, L. S., Dahiphale, S. M., Patel, D. J., … & Dahiphale, S. M. (2023). Postpartum mood disorders: insights into diagnosis, prevention, and treatment. Cureus, 15(7).

Johansen, S. L., Stenhaug, B. A., Robakis, T. K., Williams, K. E., & Cullen, M. R. (2020). Past psychiatric conditions as risk factors for postpartum depression. The Journal of Clinical Psychiatry, 81(1). https://doi.org/10.4088/jcp.19m12929

Sharma, V., Mazmanian, D., Palagini, L., & Bramante, A. (2022). Postpartum psychosis: Revisiting the phenomenology, nosology, and treatment. Journal of Affective Disorders Reports, 10, 100378. https://doi.org/10.1016/j.jadr.2022.100378

Uccella, S., Cordani, R., Salfi, F., Gorgoni, M., Scarpelli, S., Gemignani, A., … & Nobili, L. (2023). Sleep deprivation and insomnia in adolescence: implications for mental health. Brain sciences, 13(4), 569.

Weber, A., Miskle, B., Lynch, A., Arndt, S., & Acion, L. (2021). Substance Use in Pregnancy: Identifying stigma and Improving care. Substance Abuse and Rehabilitation, Volume 12, 105–121. https://doi.org/10.2147/sar.s319180

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

NU 665 WEEK 13: Crisis Management Case Study

Value: 100 points

Due: Day 7

Grading Category: Case Studies

Instructions

In this assignment, you will review the Crisis Case Study and analyze the data to determine the health status of the patient. You will need a minimum of two scholarly references to support your work.

  • Use the NU665C Crisis Case Study Questions (Word) document to complete the case study assignment.
  • Follow the requirements posted in the rubric.
  • Interactive case studies should be five to seven pages depending on the complexity of the case. This is excluding title and references pages.

All papers must conform to the most recent APA standards.

Please refer to the Grading Rubric for details on how this activity will be graded.

Module 2: HCR 561: Discussion 2

/in /by

Module 2: HCR 561: Discussion 2

In March 2006, a Phase I clinical trial was conducted at Northwick Park Hospital in London to test a drug called TGN1412, developed by the German company TeGenero. The study was sponsored by Parexel, a U.S.-based clinical research organization. The research aimed to test the safety of the immune-boosting drug in humans. Eight healthy male volunteers participated, but six of them experienced life-threatening side effects, including organ failure, within hours of receiving the drug. The trial was meant to test the drug’s ability to treat conditions like leukemia and rheumatoid arthritis by stimulating the immune system (Suntharalingam et al., 2006). (Link: Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412 | New England Journal of Medicine

The cultural climate in 2006 supported rapid innovation in biotechnology and medicine. There was growing public and governmental interest in accelerating drug development. However, this also led to less scrutiny on trial safety in some cases. The pharmaceutical industry was under pressure to deliver breakthrough treatments, and clinical trial outsourcing was common. In this context, researchers may have felt pressure to move quickly through early-phase testing, possibly contributing to ethical oversights (Meslin & Johnson, 2008). Several ethical concerns emerged from this trial. The most significant was that the drug caused catastrophic immune reactions in all participants, raising concerns about inadequate preclinical testing and poor risk assessment.

This study violated the Declaration of Helsinki, which states that research risks must be minimized and fully explained (Ashcroft, 2008). It also breached the Common Rule, especially regarding informed consent and subject protection (Porter & Koski, 2008). Participants were not fully informed about the drug’s novel mechanism and the potential severity of side effects. Both the Declaration of Helsinki and the Common Rule were in effect in 2006. To make the trial more compliant, researchers should have conducted more extensive animal testing and used a staggered dosing schedule for human participants. Improved risk communication and ethical review could have reduced harm and ensured better protection for the volunteers (Emanuel, Wendler, & Grady, 2008).

References

Ashcroft, R. E. (2008). The declaration of Helsinki. The Oxford textbook of clinical research ethics, 141-148.

Emanuel, E. J., Wendler, D., & Grady, C. (2008). An ethical framework for biomedical research. Oxford textbook of clinical research ethics (pp. 123–135). Oxford University Press.

Meslin, E. M., & Johnson, S. (2008). National bioethics commissions and research ethics (pp. 187-197). The Oxford textbook of clinical research ethics.

Porter, J. P., & Koski, G. (2008). Regulations for the Protection of Humans in Research in the United States (Vol. 156). New York/Oxford: Oxford University Press.

Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New England Journal of Medicine, 355(10), 1018-1028. DOI: 10.1056/nejmoa063842

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

Module 2: HCR 561: Discussion 2

HCR 553 Discussion 2 Contract Manufacturing: Controlling for Quality

/in /by

HCR 553 Discussion 2 Contract Manufacturing: Controlling for Quality

  1. How can the research site determine and ensure that the investigational drug being tested is in compliance with CGMP and meets Quality Guidelines?

The research site must check the process, review records, and involve all partners to prove that an investigational drug is ready for use and complies with quality standards. Even though the site does not create the product, it can adopt several proactive measures as follows:

Review and Request Documentation

Following the 2016 FDA recommendation, the research site can use the Quality Agreement in its review. The roles and responsibilities of the sponsor and contract facility are explained in this document. It allows everyone to know and do their part according to Current Good Manufacturing Practice (CGMP) guidelines (Ahmed, 2024).

Each batch of the investigational product (IP) should have a Certificate of Analysis (COA) on record with the site. COAs ensure that the drug is what it is supposed to be, meets potency standards, is pure, and lives up to safety requirements.

Verify Training and Competence

According to Ogg (2005), competency depends heavily on training. Personnel dealing with investigational product (IP) must be confirmed as being qualified to handle and train others in the safe storage and handling of medication (either “Competent” or “Competent to Train”) (Ahmed, 2024).

Monitor Storage and Handling Practices

Storing products in facilities under the recommended conditions by manufacturers and reporting any temperature changes is important for research sites. Proper storage of the drug is part of CGMP, and this applies at every site during the drug’s life.

  1. Does the site need to be concerned about the quality of the drug? Explain.

Yes, the site has to make sure the drug is of high quality, mainly for ethical and legal reasons, not just for its manufacturing standpoint.

Ethical Obligation to Subjects

The safety and well-being of research subjects is the main responsibility of both the principal investigator and study staff. Low-quality drugs may cause the treatment to fail, result in unexpected side effects, or lead to harm, potentially endangering all the subjects and the study’s results (Ogg, 2005).

Quality Impacts Safety Reporting

Since they track adverse events (AEs) and serious adverse events (SAEs), it is important for sites to tell the difference between an adverse event caused by the drug and a unique reaction of the patient. If the quality is not verified, safety data can be easily misinterpreted or misleading.

Conclusion

Since the manufacturing process happens outside, monitoring the quality of products as they are used is very important. Sites are required to cooperate with sponsors to ensure they follow current good manufacturing practice (CGMP) expectations by giving good training, checking all records, and regularly monitoring quality. These efforts not only protect the research subjects but also uphold the scientific validity and ethical standards of clinical trials.

References

Ahmed, R. (2024). Ensuring Quality Medicine is not a Single Event but Rather Combines Effects of a Pharmaceutical Company. Deleted Journal, 2(2), 226–241. https://doi.org/10.56778/rjhs.v2i2.360

https://www.fda.gov/media/86193/download

Ogg, G. (2005). A practical guide to quality management in clinical trial research. CRC Press.

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

HCR 553 Discussion 2 Contract Manufacturing: Controlling for Quality

HCR 561 Module 3: Discussion Board 3

/in /by

HCR 561 Module 3: Discussion Board 3

Introductory Statement and Position

I recommend that the Amazing IRB allow Dr. Tarry’s involvement in the study, while adding some conditions to maintain ethical practices and supervision. While the approach to styling the form is not typical in the United States, the required regulatory parts were included, and the SAIRB approved it in line with local rules. Since Dr. Tarry will have no direct contact with participants and the research offers substantial potential benefits, it is reasonable to approve the study with conditions. These should include ongoing verification that the consent process remains consistent with South American regulations and the cultural expectations of the indigenous community.

Ethical Issues and Points of Conflict

The ethical issues here are mostly about upholding local standards, supporting the rights of vulnerable populations, and guaranteeing the independence of the IRB. There is tension because the Amazing IRB wants a consent form to match U.S. standards, and the SAIRB prefers to follow their cultural approach. Concern remains about how informed consent is given, as remote indigenous people may not fully comprehend what participation in genomic research would mean for them. Still, demanding U.S.-style consent could limit local, cultural, and ethical choices. There is also the debate about whether Dr. Tarry should bear responsibility for informed consent, which is not under his direct control, given that his part is only to study anonymized samples.

Interested Parties and Their Reasonable Expectations

  • SAIRB: Expects that in collaborating with others, their ethical processes and authority should be respected.
  • SA Research Team: Expect that their research partners will obey local legal and ethical standards and that joint work will improve how their study is conducted.
  • Amazing IRB: Demands that every research project with international partners comply with ethical standards and safeguards human subjects.
  • Indigenous Participants: They expect their beliefs and culture to be treated with respect and that their data will not be abused but used for the benefit of their people.
  • Tarry: Expects that institutions will support ethically important research, particularly if the local IRB has approved it.

Probable Consequences Depending on IRB Decision

Once the study is approved by the Amazing IRB, it will allow for cooperation between researchers globally, which could achieve important medical progress for the indigenous community. Providing relevant safeguards will demonstrate respect for pluralism in ethics. Still, there may be concerns about reputation if the U.S. endorses a consent process that others believe is somewhat unclear. If research is rejected by the IRB, it may prevent or postpone key studies, harm relationships with other countries, and deny access to improved technology to those who need it the most. This could indicate a lack of respect for the way the SAIRB makes decisions and the various cultural standards present in ethics.

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

HCR 561 Module 3: Discussion Board 3

HCR 561 Discussion 3: Quality by Design

/in /by

HCR 561 Discussion 3: Quality by Design

Using Quality by Design (QbD) means taking a planned and systematic approach to ensuring the quality of pharmaceutical products and clinical trials. The ICH E8(R1) guidance emphasizes that using Quality by Design helps plan clinical trials in a way that identifies important factors affecting participant safety, data accuracy, and trial outcomes early on. This approach reduces the need to depend only on final quality checks (Whitehead et al., 2023).

“Quality must be built in” means that you should design quality from the start, not just add it in later. This approach is also supported by the FDA’s document, “Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring,” released in 2013. It outlines the need for planning and careful oversight using risk assessment to make sure trials are performed properly and deliver useful results from the beginning (Whitehead et al., 2023).

To improve the standard of a clinical trial, certain significant practices should be incorporated:

Clear Objectives and Protocol Design: Clarify what the study is trying to achieve and confirm that the protocol follows scientific and ethical standards. As required by ICH E6(R2) Good Clinical Practice, the protocol should spell out the steps to be taken, the study outcomes, who can take part, and the statistical methods to lessen discrepancies during the study (Bhatt, 2023).

Risk Assessment and Critical Data Identification: Find out early in the process which data and systems end up being critical and what threats they might face. ICH E8(R1) states that “Critical to Quality” (CtQ) factors are important because they ensure good results and everyone remains safe (Whitehead et al., 2023).

Stakeholder Collaboration: It is important to bring experts from various departments (such as clinical operations, data management, and regulatory affairs) into trial planning early to ensure the process will be possible and follow all relevant regulations (Bhatt, 2023).

Continuous Improvement: Monitor the trial process using metrics and indicators to ensure it keeps improving during the trial lifecycle (Ogg, 2005).

References

Bhatt, A. (2023). The revamped Good Clinical Practice E6 (R3) guideline: Profound changes in principles and practice!. Perspectives in Clinical Research, 14(4), 167-171.

Ogg, G. (2005). A practical guide to quality management in clinical trial research. CRC

Press.

Whitehead, M., Suprin, M., Mistree, T., Kearns, M. M., Marini, G., Goffe, C., Pillwein, M., & Abdul-Shukkoor, V. (2023). The Renovation of Good Clinical Practice: A framework for key components of ICH E8. Therapeutic Innovation & Regulatory Science, 58(2), 303–310. https://doi.org/10.1007/s43441-023-00561-x

HCR 561 Discussion 3: Quality by Design

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

HCR 553: Quality in Manufacturing Product Control

/in /by

HCR 553: Quality in Manufacturing Product Control

Product Control

Any clinical trial’s success, safety, and integrity depend greatly on the quality of investigational medical products produced during manufacturing. Those working in clinical settings stay away from manufacturing processes, and their understanding of controlling the products is necessary for the care of participants. In today’s organizations, following current Good Manufacturing Practices and Food and Drug Administration (FDA) guidelines requires managing essential elements like ingredients, conducting product testing, regulating batches, and checking storage conditions. Other duties include ensuring controlled access, proper packaging, handling, labeling, shipping, proper training for the team, standardized procedures, accurate documentation, and adopting inspections. In this paper, we examine the controls and procedures used to ensure good product quality, following regulations from the U.S. Food and Drug Administration (FDA), the International Council for Harmonisation (ICH), and Good Clinical Practice (GCP).

  1. Regulatory Foundations of Product Control

The FDA’s 21 CFR Parts 210 and 211 set out the guidelines for current Good Manufacturing Practices (cGMP) standards in the manufacture of drugs. There should be strict controls put in place for all batches of the Investigational Medicinal Product (IMP) so that the requirements are met. According to the ICH Q10 (Pharmaceutical Quality System), quality management should be included in every part of manufacturing, especially during the monitoring process (U.S. Congress, 2013). Under the Drug Supply Chain Security Act (DSCSA) and 21 CFR Part 312, all IMPs used in clinical trials are expected to be labeled, packaged, and tracked properly.

  1. Factors and Controls in Product Control

Product Materials and Testing: Every material in manufacturing is required to uphold strict standards of quality. As outlined by the FDA (2016), all active pharmaceutical ingredients and excipients have to be checked for their identity, strength, purity, and quality before they are used. To ensure no cross-contamination or adulteration, incoming material control includes qualifying suppliers, sampling incoming goods, and testing using approved methods. Release testing is done on investigational products to confirm that they comply with the necessary standards before they are used in a clinical setting.

Batch Control and Documentation: For every manufactured batch, a unique batch record is needed to track production, control, and release processes. It covers batch numbers, descriptions of the components, manufacturing instructions, any deviations, and the test results. According to 21 CFR §211.188, these records must be accurate, reviewed, and retained for traceability (FDA, 2016). It is also important to store samples in batches so that they can be analyzed again if something negative happens during a clinical trial.

Storage and Access Control: Every product needs appropriate storage conditions to remain stable. According to the directions in the investigational brochure and packaging label, Investigational Medicinal Products (IMPs) must be stored at the correct temperature, humidity, and under the necessary protection from light. Storing products properly according to 21 CFR §211.142 means you need data loggers and alarms to monitor and record temperature and humidity conditions in your facility (U.S. Congress, 2013). Moreover, it is important to make sure that access to restricted areas is controlled in accordance with GCP and ISO 13485:2016.

Packaging, Labeling, and Shipping: Accurate and correct packaging and labeling are necessary for keeping things legal and safe for patients. The law under 21 CFR §312.6 requires that labels not be false or misleading and must include the statement: “Caution: New Drug – Limited by Federal (or United States) law to investigational use (FDA, 2022).” Products need to be protected from the effects of the environment during shipment. Cold chain integrity must be preserved during transport when necessary, and the chain of custody should be consistently documented.

III. Quality Integration in Product Control   

Quality Management Systems and SOPs: All the aspects of running a product are connected in a powerful Quality Management System. For any manufacturing or handling process, Standard Operating Procedures (SOPs) play a key role in keeping everything consistent and in compliance. The SOPs should explain clear steps for material testing, batch approval criteria, deviation handling, making changes, complaint resolution, and how documents are kept (Ogg, 2005). ICH Q7 and ISO 9001:2015 make it especially important to focus on continuous improvement and preventive measures.

Staff Training and Qualifications: All teams working in product control must be well-educated in Good Manufacturing Practices (GMPs), FDA regulations, and the duties specific to their positions. As outlined by 21 CFR §211.25, employees should be educated and trained to carry out their work (FDA, 2022). Training staff each year, recording their skills, and assessing them helps ensure top standards and limits mistakes due to human error.

Quality Control and Assurance Activities: Quality can be achieved by putting control checks at every milestone. Quality Control (QC) makes sure testing and inspection live up to release standards, and Quality Assurance (QA) validates that all SOPs, documentation, and actions follow set rules (Mullaivendan & Morais, 2022). Keeping an eye on quality requires internal reviews, checks on vendors, managing breakdowns, and using CAPA (Corrective and Preventive Action) processes.

Documentation and Recordkeeping: Good traceability and accountability depend on well-recorded and up-to-date documents. All steps from collecting supplies to shipping must be logged in compliance with ALCOA (Attributable, Legible, Contemporaneous, Original, Accurate) standards (U.S. Congress, 2013). The use of electronic systems for records in drug production must comply with the rules mentioned in 21 CFR Part 11, which focus on audit, security, and validation aspects.

Inspections and Continuous Improvement: Regular internal checks and observations by the FDA help to find any weaknesses in meeting regulations. FDA conducts regular audits of trials through its Bioresearch Monitoring (BIMO) Program, ensuring proper handling of manufacturing files, investigation of drug storage, and record keeping of the products. Any findings should be resolved rapidly by putting Corrective and Preventive Action (CAPA) plans into action (Mullaivendan & Morais, 2022). Moreover, always aiming for improvement leads to better risk identification and more reliable processes.

  1. The Role of Clinical Site Staff

Even though the manufacturing is done elsewhere, site staff still ensure that the investigational product is received safely and given to patients correctly. Ensuring staff understand how to handle products, reconcile, and keep the right records helps them comply with the investigational plan (Ogg, 2005). Team members should be aware of all rules in the Investigator’s Brochure and understand the product usage, storage, and disposal protocol.

Staff at the site may also have to report temperature deviations, damaged items, or labeling errors, which need to be recorded and relayed to the sponsor. During these audits, inspectors often check Investigational Medicinal Product (IMP) logs to ensure all products are stored correctly and their safety and data are maintained.

Conclusion

For clinical research to be successful and for people participating in studies to be safe, the process of product control is vital. Integrating quality systems from the beginning of the supply chain to the final delivery ensures adherence to Food and Drug Administration (FDA) current Good Manufacturing Practices (cGMPs), the International Council for Harmonisation (ICH) rules, and other worldwide regulations for sponsors and manufacturing groups. While not involved in production, clinical site staff should nevertheless recognize how vital these controls are to the study’s safety, efficiency, and compliance with regulations.

References

Food and Drug Administration. (2016). Guidance for Industry: Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. https://www.fda.gov/media/71518/download

Food and Drug Administration. (2022). Code of Federal Regulations Title 21, Parts 210, 211, 312. https://www.ecfr.gov/current/title-21

Mullaivendan, P., & Morais, D. S. (2022). A Short Review On Vendor Evaluation, Approach, Criteria And Questionnaire. (2022). Int. J. Life Sci. Pharma Res, 12(3), 1-10.

Ogg, G. (2005). A practical guide to quality management in clinical trial research. CRC

Press.

U.S. Congress. (2013). Drug Supply Chain Security Act. Public Law No: 113-54.

HCR 553: Quality in Manufacturing Product Control

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

HCR 553 Quality Management Plan

/in /by

HCR 553 Quality Management Plan

Phase III Study: XYZ vs. Corticosteroids for Lateral Epicondylitis

Overview and Summary of the Plan

The present Quality Management Plan (QMP) is a straightforward plan designed to support the integrity and quality of a Phase III randomized, double-blind, multi-center clinical trial. This trial involves the investigational product XYZ compared with corticosteroids in the management of lateral epicondylitis (LE). The study will foster the principles of ethical conduct of research activities, patient safety, and the validity of the data. The sponsor requirements pertaining to the administration of this plan have a strong basis in international and U.S. laws and regulations. These include the International Council for Harmonisation (ICH) E6(R2), Good Clinical Practice guidelines, and the FDA regulations under 21 CFR Parts 312 and 50.

The quality initiatives in the plan go hand in hand with the objective of the trials to ensure they cover the issues of scientific validity and ethical issues. The study design and conduct are also based on the concepts of quality-by-design, where the quality is incorporated into the study design at the early phase of the study (Guideline, 2015). This proactive risk-based strategy allows the identification of potential pitfalls before they can affect the trial, and makes quality management an integrated component of the clinical research process, not an afterthought.

Identification of Critical Quality Factors and Risk Factors

Several critical quality factors (CQFs) have been outlined, and each of them poses risks that, without mitigation, may jeopardize the integrity of the trial. Proper evaluation of participant eligibility is one of the most important critical quality factors (CQFs). A screening misclassification can allow ineligible subjects to be enrolled and raise safety concerns; it can also lead to inefficacy data that may be flawed.

The informed consent procedure is also essential. This should not be a mere formality, as this is a regulatory and ethical pillar, which is found in 21 CFR 50.20 (21 CFR Part 312 — Investigational New Drug Application, n.d.). Unless done properly, the consent process might not be ethical, thus compromising the autonomy of the participants and rendering their participation invalid.

Data accuracy presents another risk area. Discrepancies or missing values in case report forms (either because of manual entry errors, incomplete reporting, or system failure) might impact statistical analyses. Another critical issue is the protocol compliance since any deviations related to the administration of the drug or visits could lead to uneven exposure to the treatment and affect endpoint values. The monitoring of adverse events provides a challenge to the safety of patients and regulatory affairs when mistaken or not reported in a timely manner, as required by 21 CFR 312.32 (21 CFR Part 312 — Investigational New Drug Application, n.d.).

Mitigation procedures involved in the plan include thorough training of investigators, real-time, electronic data capture (EDC) systems, and continued site-support visits to promote uniformity and responsiveness.

Quality Metrics and Indicators of Success

The quality of a given clinical trial can only be assured by the regular measurement of objective and quantifiable indicators. Among these measures is the protocol deviation rate, which quantifies how far the conduct of the study moves away from the approved protocol. It is computed by dividing the number of deviations by the number of subject visits or enrolled participants and multiplying by 100 to get a percentage. As an example, a site with a 12% deviation rate, whether through missed assessments or unauthorised medication changes, will indicate that further, specific retraining or operational assessment is required.

Informed consent compliance is another critical measure that makes sure that all the study participants are properly informed and have consented according to the most current versions of the IRB-approved protocols. This is confirmed by source data verification when monitoring the sites. In case, say, three participants turn up as having signed old consent forms, the compliance rate would be 94 percent, triggering an immediate corrective measure. Follow-up of complete and properly dated and signed forms is essential, both ethically and regulatorily.

The promptness of reporting adverse events (AEs) and serious adverse events (SAEs) is also one of the indicators of site performance and patient safety. The metric is quantified by assessing the time required between AE onset and submission of the report with regulatory standards, including those outlined in 21 CFR 312.32. For instance, a serious adverse event reported after 10 days, when it should have been reported within 7 days, would indicate that there is a variance in the expected timelines and the safety processes and training at the site should be reviewed.

Data query resolution time is a direct measure of efficiency and accuracy with which sites perform their data duties. It is established by finding the average of the time a query on data is posted in the electronic data capture (EDC) system and the time the query is solved. When a site has an average of five days or fewer, that indicates a responsiveness that is sufficient, whereas higher numbers can indicate workflow inefficiency or understaffing and require some form of intervention to ensure the quality and timeliness of the database.

Lastly, the result of the internal and external audit will give a complete picture of the operational and regulatory well-being of the trial. The audit results are classified as minor, major, or critical and are recorded and evaluated not only by their recurrence but also by the effectiveness and timeliness of corrective action taken. Indicatively, the inability to resolve inconsistencies in source documents within 30 days following an audit may indicate systemic weaknesses, whereas prompt and adequate resolution would indicate the culture of ongoing quality improvement.

Risk Management and Oversight Strategies

The quality-by-design approach to risk management has been described as the most effective model in this trial, whereby the risks are identified and prioritized prior to the start of the trial. This philosophy is compliant with ICH E6(R2), and it is executed by various supervision strategies.

Centralized statistical monitoring is used to identify trends and outliers that could signal data integrity issues or emerging safety signals. These anomalies can be the basis of targeted, on-site monitoring to examine the possible problem on site in real time. Risk-based monitoring tools aid in directing monitoring resources to where they are required most, resulting in maximum efficiency and maximum coverage.

The independent Data Monitoring Committee (DMC) is central. The DMC oversees the early detection of safety signals and proper courses of action by reviewing unblinded interim data and comparing the occurrence of actual events to pre-specified boundaries (Emanuel, 2008). Another quality control is offered by scheduled and for-cause audits. Such audits not only examine the protocol compliance, but also assess the data systems, delegation records, and training records in order to determine compliance with all operational areas.

Whenever deviation or mistakes are noted, there is the activation of Corrective and Preventive Action (CAPA) systems. CAPA is formulated upon root cause analyses and pursued with efficacy checks to ensure resolution. It is a powerful method that enables dynamic quality management of the study.

Quality Improvement and CAPA Integration

The task of quality improvement cannot be considered as a static one, as it is an ongoing process that spans throughout the stages of the clinical trial. This work is underpinned by the pre-study site trainings, which aim to create a common comprehension of the trial expectations (Ogg, 2005). These sessions are meant to ensure there is clarity on the details of operation, improve the meaning assigned to protocols, and develop a sense of shared ownership of quality.

Some of the enhancements include the simplification of language used in protocols to ensure that they can be easily comprehended and reduce the possibility of being misconstrued. The electronic case report forms (eCRFs), including the pre-programmed validation rules and user prompting, have also been developed, which reduces the risks of entry errors and incomplete data submission.

The study will apply the structured root cause analysis tools, including the 5 Whys and Fishbone Diagrams in situations of quality concerns to establish the root causes of the issue. When this is detected, a certain Corrective and Preventive Action (CAPA) plan is implemented. All these plans involve some timelines, duties, and follow-up evaluations, which are necessary to ensure that the issue is eradicated fully and there is no possibility of it happening again. These initiatives suggest the proactive mode of quality management that the Food and Drug Administration (FDA) is fostering in its guidance on quality systems and CAPA processes (Ogg, 2005).

This kind of proactive attitude not only assists in rectifying the problems as they arise, but it also generates an environment where the enhancement of quality becomes an issue for all the personnel involved in the study.

Safeguarding Patient Safety Through Data Quality

Patient safety is a regulatory and ethical requirement. The given plan fosters the well-being of patients because its data collection and monitoring procedures are rigorous and consistent with the requirements of 21 CFR 312.32, as well as the ethical principles of the Belmont Report and the Declaration of Helsinki (21 CFR Part 312 — Investigational New Drug Application, n.d.). Safety data are systematically reviewed, and the review system has in-built alerts that inform the investigators about the missing or late safety reports regarding adverse events or serious adverse events.

ANCOVA (Analysis of Covariance) is a robust statistical model that can be effectively used to account for the effects of treatment, and yet, baseline variability is taken into consideration. The training of investigators will focus on the proper identification and classification of safety events, and it will aid in ensuring consistency among the different study sites. Oversight from the Data Monitoring Committee (DMC) offers an additional safeguard, providing impartial review and guidance based on interim data trends (Emanuel, 2008). Such a combination approach, consisting of human diligence and technical precision, can enable the study to meet the principle of beneficence, maximizing the good and minimizing the potential harm to the subjects.

Conclusion

The current Quality Management Plan is a core element of the Phase III trial that compares XYZ to corticosteroids in lateral epicondylitis. The plan provides a way forward in achieving reliability of study outcomes and protection of participants, grounded on regulatory advice, ethical values, and operational best practices. Through integrating quality in the course of the trial, such as in the planning, conduct, analysis, and reporting, the sponsor will have demonstrated a specific endeavour to assure scientific integrity and safeguard human subjects.

With the focus on the essential risk factors, continuous betterment, and efficient supervision, the Quality Management Plan (QMP) helps to produce the reputable evidence that will be submitted to the regulatory agency and eventually utilized in clinical practice. Lastly, it will ensure that all the subjects who will take part in the research will be handled with utmost care, respect, and ethical consideration of the highest degree.

References

21 CFR Part 312 — Investigational new Drug Application. (n.d.). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312

Emanuel, E. J. (Ed.). (2008). The Oxford textbook of clinical research ethics. Oxford University Press.

Guideline, I. H. (2015). Integrated addendum to ICH E6 (R1): guideline for good clinical practice E6 (R2). Current Step, 2, 1-60.

Ogg, G. (2005). A practical guide to quality management in clinical trial research. CRC

Press.

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

 

 

HCR 553 Quality Management Plan

Module 4 Discussion Board 4 HCR 553

/in /by

Module 4 Discussion Board 4 HCR 553

Selected Commitment from Section 9 of Form FDA 1572:
“I agree to inform any patients, or any persons used as controls, that the drugs are being used for investigational purposes and I will ensure that the requirements relating to obtaining informed consent in 21 CFR Part 50 and institutional review board (IRB) review and approval in 21 CFR Part 56 are met.”

Importance of the Protection of the Research Subject

This principle lies at the basis of ethical clinical research and the safety of human subjects. Informed consent is not just a formality, but a sign that individuals comprehend the nature of the study, such as the fact that the drug is investigational and not accepted for use by the general population. With this knowledge, subjects are able to make voluntary or autonomous decisions concerning their participation, in line with the ethical principles of the Belmont report, especially respect for persons and autonomy (Guidance, 2008). It also promotes transparency and trust between investigators and the subjects, which limits the aspect of exploitation. Furthermore, the process of informed consent safeguards patients against unanticipated outcomes since they are made to understand the possible risks, benefits, alternatives, and that they have the right to abandon the study without penalty at any point.

Investigator Activities and Responsibilities

As part of this commitment, the investigator must first ensure that both the clinical investigation and the informed consent document are reviewed and approved by an Institutional Review Board (IRB). The IRB must meet the regulatory standards outlined in 21 CFR Part 56 to safeguard the rights and welfare of research subjects. Before the enrolment of the subjects, a detailed description of the study should be presented in a language that the subjects can easily comprehend and devoid of undue influence as stipulated by 21 CFR 50.20 (Buchneva, 2025). The content of informed consent must meet the criteria under 21 CFR §50.25, including disclosures about the investigational nature of the drug, foreseeable risks or discomforts, and who to contact in the event of a research-related injury.

The researcher is obliged to keep signed and dated consent forms of every subject and reconsent them in case of significant new information. Any changes to the protocol or consent form must receive prior Institutional Review Board (IRB) approval unless changes are necessary to eliminate immediate hazards to subjects (Buchneva, 2025). Noncompliance may result in Food and Drug Administration (FDA) enforcement action and may compromise the ethical conduct of the research.

References

Buchneva, N. (2025, January 14). To sign or not to sign FDA Form 1572? Applied Clinical Trials. https://www.appliedclinicaltrialsonline.com/view/sign-or-not-sign-fda-form-1572

GUIDANCE, D. (2008). Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions-Statement of Investigator.

Module 4 Discussion Board 4 HCR 553

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

HCR 561 Discussion Board 5

/in /by

HCR 561 Discussion Board 5

Not all researchers are fully equipped to determine when a participant has diminished decision-making capacity. Investigators and coordinators are often trained in clinical procedures but are not trained in recognizing cognitive impairments. Laura Holtz highlights that these determinations can be made effectively by the frontline research staff, particularly the coordinators, when they are adequately trained and empowered (SOCRA, 2019). Since they continuously interact with participants, frontline research staff are in a position to see small shifts in thought and cognition, especially throughout the process of informed consent.

Impaired decision-making ability can manifest itself in confusion, failure to repeat study procedures, or lack of confidence in making voluntary choices. Another promising approach that Holtz points out includes the teach-back tactic, during which the participants will have to repeat information using their own words. This aids in checking understanding and reveals the understanding gaps.

Consent management in the context of persons who are limited in their decision-making ability should be approached carefully and on a case-by-case basis. Holtz supports the use of legal representative’s authorization (LARs) where the subject is considered incapable of consenting (SOCRA, 2019). Substituted judgment and the best-interest standard are essential ethical mechanisms in instances such as: decisions must conform to the identified values, wishes, or preferences of the participant. The record should show not just what decision was made, but also how the decision was reached. This helps respect and reflect the participant’s experience, especially when they have limited decision-making ability (“Research Involving Individuals with Questionable Capacity to Consent: Points to Consider,” 2009). In the case of partial or inconsistent capacity, researchers may want to take into account a graded consent scheme, in which people offer assent together with the legal representative’s authorization (LAR) consent, thereby maximizing dignity and autonomy. The second presenter on pediatric ethics explains that age or thinking ability should not automatically exclude someone from research. Instead, each person should be involved based on what they understand and how they best communicate (CCLG, 2016).

Ultimately, ethical research also requires a balance between protection and inclusion. Instead of excluding people just because of their age or mental condition, we should assess each person individually. This helps support their independence and ensures we follow the Belmont Report’s principles of fairness, respect, and care.

References

CCLG. (2016, June 30). Ethical considerations of involving children in research [Video]. YouTube. https://www.youtube.com/watch?v=AOyUMfI3ogo

Research involving individuals with questionable capacity to consent: Points to consider. (2009). [Dataset]. In PsycEXTRA Dataset. https://doi.org/10.1037/e651372011-001

SOCRA. (2019, November 6). Including Vulnerable Subjects with Cognitive Impairment in Research [Video]. YouTube. https://www.youtube.com/watch?v=OTO40lig1Xw

HCR 561 Discussion Board 5

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER